I-Mab to Present at the BTIG Virtual Biotechnology Conference
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company's management will engage in a fireside chat and one-on-one meetings on Tuesday, July 29, 2025, at 10:00 AM ET.
The presentation will be available via webcast on I-Mab's website under the News & Events section, remaining accessible for 90 days following the event.
I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale con sede negli Stati Uniti specializzata in agenti immuno-oncologici di precisione per il trattamento del cancro, ha annunciato la sua partecipazione alla prossima BTIG Virtual Biotechnology Conference. Il management dell'azienda parteciper脿 a una conversazione informale e a incontri individuali marted矛 29 luglio 2025 alle 10:00 AM ET.
La presentazione sar脿 disponibile in webcast sul sito web di I-Mab nella sezione News & Events e rester脿 accessibile per 90 giorni dopo l'evento.
I-Mab (NASDAQ: IMAB), una empresa biotecnol贸gica global con sede en EE. UU. especializada en agentes de inmuno-oncolog铆a de precisi贸n para el tratamiento del c谩ncer, ha anunciado su participaci贸n en la pr贸xima Conferencia Virtual de Biotecnolog铆a BTIG. La direcci贸n de la empresa participar谩 en una charla informal y reuniones individuales el martes 29 de julio de 2025 a las 10:00 AM ET.
La presentaci贸n estar谩 disponible v铆a webcast en el sitio web de I-Mab en la secci贸n de Noticias y Eventos, y podr谩 accederse a ella durante 90 d铆as despu茅s del evento.
I-Mab (NASDAQ: IMAB)電� 鞎� 旃橂毳� 鞙勴暅 鞝曤皜 氅挫棴頃晹鞝滌棎 韸鬼檾霅� 氙戈淡 旮半皹鞚� 旮�搿滊矊 氚旍澊鞓ろ厤 旮办梾鞙茧, 雼り皜鞓る姅 BTIG 臧�靸� 氚旍澊鞓ろ厡韥� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳潃 2025雲� 7鞗� 29鞚� 頇旍殧鞚� 鞓れ爠 10鞁�(霃欕秬鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘瓿� 鞚茧寑鞚� 氙疙寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
氚滍憸 雮挫毄鞚� I-Mab 鞗轨偓鞚错姼鞚� 雺挫姢 氚� 鞚措菠韸� 靹轨厴鞐愳劀 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 頉� 90鞚� 霃欖晥 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
I-Mab (NASDAQ : IMAB), une entreprise biotechnologique mondiale bas茅e aux 脡tats-Unis sp茅cialis茅e dans les agents d'immuno-oncologie de pr茅cision pour le traitement du cancer, a annonc茅 sa participation 脿 la prochaine BTIG Virtual Biotechnology Conference. La direction de l'entreprise participera 脿 une discussion informelle et 脿 des r茅unions individuelles le mardi 29 juillet 2025 脿 10h00 ET.
La pr茅sentation sera disponible en webcast sur le site web d'I-Mab dans la section Actualit茅s & 脡v茅nements, et restera accessible pendant 90 jours apr猫s l'茅v茅nement.
I-Mab (NASDAQ: IMAB), ein in den USA ans盲ssiges globales Biotech-Unternehmen, das sich auf pr盲zise Immunonkologie-Medikamente zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der bevorstehenden BTIG Virtual Biotechnology Conference angek眉ndigt. Das Management des Unternehmens wird am Dienstag, den 29. Juli 2025, um 10:00 Uhr ET an einem Fireside-Chat und Einzelgespr盲chen teilnehmen.
Die Pr盲sentation wird als Webcast auf der Website von I-Mab unter der Rubrik News & Events verf眉gbar sein und ist 90 Tage nach der Veranstaltung abrufbar.
- None.
- None.
ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the 鈥淐ompany鈥�), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab鈥檚 management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
Conference details are as follows:
BTIG Virtual Biotechnology Conference
Format: Fireside Chat and one-on-one meetings
Date: Tuesday, July 29, 2025
Time: 10:00 AM ET
Webcast Link: Available on the News & Events page of the I-Mab website
The webcast of the event will be accessible from News & Events page of the听I-Mab听website for 90 days.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company鈥檚 differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
For more information, please visit and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
| PJ Kelleher | 听 |
| LifeSci Advisors | 听 |
| +1-617-430-7579 | 听 |
| [email protected] | 听 |
| [email protected] | 听 |
FAQ
When is I-Mab (IMAB) presenting at the BTIG Virtual Biotechnology Conference 2025?
How can investors access I-Mab's BTIG conference presentation?
What type of meetings will I-Mab participate in at the BTIG Virtual Biotechnology Conference?
What is I-Mab's (IMAB) main business focus?
